DILTIAZEM HYDROCHLORIDE | N020062 | BAUSCH HEALTH US LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Hyman, Phelps & McNamara, P.C. FDA-2021-P-0677 On behalf of a client, the law firm Hyman, Phelps & McNamara filed a suitability petition pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act and 21 C.F.R. § 314.93 requesting that FDA declare Diltiazem Hydrochloride Extended-Release Capsules, 60 mg, suitable for submission i | Suitability | 2021-07-08 | Open | Hyman |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.